Loading...
TNYA logo

Tenaya Therapeutics, Inc.NasdaqGS:TNYA Stock Report

Market Cap US$167.6m
Share Price
US$0.77
US$4
80.7% undervalued intrinsic discount
1Y79.5%
7D-9.9%
1D
Portfolio Value
​
View

Tenaya Therapeutics, Inc.

NasdaqGS:TNYA Stock Report

Market Cap: US$167.6m

Tenaya Therapeutics (TNYA) Stock Overview

A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More details

TNYA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 60.87% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($225K)


TNYA Community Fair Values

Create Narrative

See what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Tenaya Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tenaya Therapeutics
Historical stock prices
Current Share PriceUS$0.77
52 Week HighUS$2.35
52 Week LowUS$0.43
Beta2.77
1 Month Change14.92%
3 Month Change31.62%
1 Year Change79.48%
3 Year Change-88.95%
5 Year Changen/a
Change since IPO-94.97%

Recent News & Updates

Analysis Article • May 05

We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Analysis Article • May 05

We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 05

Tenaya Therapeutics: Risky But Promising Cardiac Gene Platform

Summary Tenaya Therapeutics develops gene therapies and small molecules for inherited cardiomyopathies. They have TN-201 for HCM, TN-401 for ARVC, and HDAC6 inhibitor TN-301. Management positions its AAV9 platform and internal manufacturing as a reusable engine for multiple cardiac genetic medicines. Thus, TNYA can potentially target several other mutation-defined patient populations at some point. However, TNYA remains pre-revenues, and it’s a thinly traded microcap. Its tight cash runway is also a concern. Lastly, the FDA put a clinical hold on TN-201. So, all of these risks ultimately nudge me towards a neutral “Hold” on TNYA for now. Read the full article on Seeking Alpha
Analysis Article • Sep 21

Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • May 20

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 23

Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 30

Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease

Summary Tenaya Therapeutics, Inc.'s TN-201 gene therapy showed promising early results in MYBPC3-HCM patients, with increased RNA expression and protein levels, but the stock remains a “Hold.”. Key data updates from the phase 1b/2 MyPEAK-1 study, including higher dosing results, are expected in 2025, potentially impacting stock performance. TNYA is also advancing TN-401 for PKP2-ARVC, with phase 1b RIDGE-1 study results anticipated in 2025, diversifying its pipeline. Financially, Tenaya had $79.5M in cash as of September 30th 2024 but may need to raise funds in early 2025, possibly leveraging the $45M credit facility it could tap into. Read the full article on Seeking Alpha
Analysis Article • Sep 18

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 04

We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 20

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Aug 08

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Mar 07

Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 06

Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 06

Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment

Tenaya Therapeutics (NASDAQ:TNYA) said the U.S. Food and Drug Administration had cleared its application to begin clinical testing of TN-301 to potentially treat heart failure with preserved ejection fraction (HFpEF). (TNYA) rose 3.1% before the bell. Tenaya has begun its first-in-human Phase 1 clinical trial of TN-301 in healthy adult participants. HFpEF is a complex disease that involves systemic inflammation, left ventricular hypertrophy, fibrosis, and diastolic dysfunction factors, and is estimated to affect more than three million people in the U.S. alone. In Stage 1, participants will receive single ascending doses (SAD) of either TN-301 or placebo.
Seeking Alpha • Aug 10

Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07

Tenaya Therapeutics press release (NASDAQ:TNYA): Q2 GAAP EPS of -$0.69 beats by $0.07.  cash, cash equivalents and investments in marketable securities were $180.9 million
Analysis Article • Aug 08

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 03

We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Nov 01

Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 06

Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms

Tenaya Therapeutics is developing therapies for rare genetic disorders and more prevalent cardiovascular diseases. The Company has three distinct but interrelated product platforms. Tenaya just closed an upsized IPO with gross proceeds of about $207 million.

Shareholder Returns

TNYAUS BiotechsUS Market
7D-9.9%1.2%1.1%
1Y79.5%34.6%28.7%

Return vs Industry: TNYA exceeded the US Biotechs industry which returned 34.6% over the past year.

Return vs Market: TNYA exceeded the US Market which returned 28.7% over the past year.

Price Volatility

Is TNYA's price volatile compared to industry and market?
TNYA volatility
TNYA Average Weekly Movement16.9%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: TNYA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: TNYA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201670Faraz Aliwww.tenayatherapeutics.com

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.

Tenaya Therapeutics, Inc. Fundamentals Summary

How do Tenaya Therapeutics's earnings and revenue compare to its market cap?
TNYA fundamental statistics
Market capUS$167.63m
Earnings (TTM)-US$83.00m
Revenue (TTM)US$225.00k
745.0x
P/S Ratio
-2.0x
P/E Ratio

Is TNYA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TNYA income statement (TTM)
RevenueUS$225.00k
Cost of RevenueUS$0
Gross ProfitUS$225.00k
Other ExpensesUS$83.23m
Earnings-US$83.00m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.38
Gross Margin100.00%
Net Profit Margin-36,891.11%
Debt/Equity Ratio0%

How did TNYA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 02:13
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tenaya Therapeutics, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
Yevgeniya LivshitsChardan Capital Markets, LLC
Emanuela BranchettiH.C. Wainwright & Co.